ANGLE PLC announces supplier agreement with AstraZeneca for prostate cancer assay
ANGLE PLC CEO Andrew Newland announces supplier agreement with AstraZeneca to develop prostate cancer assay
The partnership between ANGLE PLC and AstraZeneca to develop the AR detection assay is significant for the advancement of prostate cancer studies and clinical oncology. This innovative development has the potential to improve the assessment of prostate cancer therapies, ultimately impacting patient care and treatment outcomes.